| Literature DB >> 28642752 |
Huan Li1, Rong Tang2, Yang Lou1, Zelin Cui2, Wenjing Chen2, Qing Hong2, Zhaohuan Zhang1, Pradeep K Malakar1, Yingjie Pan1,3,4, Yong Zhao1,3,4.
Abstract
Vibrio parahaemolyticus is one of the most important pathogen for seafood-borne gastroenteritis in Shanghai and the rest of the world. A total of 42 V. parahaemolyticus strains were isolated from 1900 fecal specimens collected from patients in Shanghai hospital presenting from January 2014 to December 2015. All isolates were evaluated for potential virulence factors [tdh, trh, and type three secretion system (T3SS) genes], typed using multilocus sequence typing (MLST) and screened for antimicrobial resistance phenotype and genotype. And for the first time, the relationship between virulence, genetic diversity and antimicrobial resistance of these isolates were identified. The results showed that 37 isolates carried the tdh gene (88.1%) and only seven isolates were positive for the trh gene. The T3SS1 and T3SS2 genes were detected in all strains and only trh-positive isolates are also containing the T3SS2β genes. MLST analysis of the 42 Shanghai isolates identified 20 sequence types (STs) with 16 novel STs and that these clinical V. parahaemolyticus strains showed high degrees of genetic diversity. All isolates expressed high levels of resistance against Ampicillin (100.0%), Streptomycin (100.0%), Cephazolin (92.9%), Kanamycin (92.8%) and Amikacin (90.5%), and eight out of 38 resistance genes (SHV, tet(B), strA, qnrA, gryA, qnrB, sulI, sulII) were detected in at least two isolates. This study confirms that antimicrobial resistance of clinical V. parahaemolyticus isolates is greater than those of environmental isolates. Furthermore, no clear correlation between antimicrobial resistance and virulence or genetic diversity was found in this study. These results add to epidemiological data of clinical V. parahaemolyticus isolates in Shanghai and highlight the need for additional mechanistic studies, especially antimicrobial resistance, to reduce the burden of disease caused by this pathogen in China.Entities:
Keywords: Vibrio parahaemolyticus; antimicrobial susceptibility; diarrhoea samples; genetic diversity; virulence
Year: 2017 PMID: 28642752 PMCID: PMC5462930 DOI: 10.3389/fmicb.2017.01043
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Information of 42 Vibrio parahaemolyticus clinical isolates.
| Name | Gender | Age | ||||
|---|---|---|---|---|---|---|
| VPC1 | Female | 57 | + | + | ||
| VPC2 | Female | 53 | + | + | ||
| VPC15 | Female | 30 | + | + | ||
| VPC16 | Female | 31 | + | + | ||
| VPC17 | Male | 56 | + | + | ||
| VPC18 | Female | 29 | + | + | + | |
| VPC19 | Male | 16 | + | + | ||
| VPC20 | Male | 13 | + | + | ||
| VPC21 | Female | 54 | + | + | ||
| VPC22 | Male | 17 | + | + | ||
| VPC25 | Female | 35 | + | + | ||
| VPC26 | Female | 36 | + | + | ||
| VPC27 | Male | 22 | + | + | ||
| VPC28 | Male | 48 | + | + | ||
| VPC29 | Male | 26 | + | + | ||
| VPC32 | Male | 57 | + | + | ||
| VPC33 | Male | 38 | + | + | ||
| VPC34 | Male | 37 | + | + | ||
| VPC35 | Male | 56 | + | + | ||
| VPC36 | Female | 47 | + | + | + | |
| VPC37 | Male | 63 | + | + | ||
| VPC38 | Female | 56 | + | + | ||
| VPC40 | Female | 58 | + | + | ||
| VPC41 | Female | 79 | + | + | ||
| VPC42 | Male | 55 | + | + | ||
| VPC43 | Male | 56 | + | + | + | + |
| VPC44 | Male | 33 | + | |||
| VPC45 | Female | 54 | + | + | ||
| VPC46 | Male | 26 | + | + | ||
| VPC47 | Female | 86 | + | + | ||
| VPC48 | Female | 45 | + | + | ||
| VPC49 | Female | 56 | + | + | + | + |
| VPC50 | Male | 46 | + | + | ||
| VPC51 | Male | 24 | + | + | ||
| VPC54 | Female | 39 | + | + | + | + |
| VPC55 | Male | 22 | + | + | ||
| VPC85 | Female | 58 | + | + | + | |
| VPC89 | Female | 46 | + | + | ||
| VPC90 | Male | 37 | + | + | ||
| VPC94 | Male | 28 | + | + | + | |
| VPC97 | Female | 26 | + | + | ||
| VPC100 | Male | 56 | + | + | ||
Distribution of T3SS genes among 42 clinical V. parahaemolyticus isolates.
| Gene | No. of strains (n = 42) | |||
|---|---|---|---|---|
| VP1670 ( | 34 | 3 | 4 | 1 |
| VP1686 ( | 34 | 3 | 4 | 1 |
| VP1689 ( | 34 | 3 | 4 | 1 |
| VP1694 ( | 34 | 3 | 4 | 1 |
| All 4 genes present | 34 | 3 | 4 | 1 |
| VP1362 ( | 34 | 2 | 3 | 1 |
| VP1339 ( | 34 | 1 | 3 | 1 |
| VP1335 ( | 34 | 1 | 2 | 1 |
| VP1327 ( | 34 | 1 | 2 | 1 |
| All 4 genes present | 34 | 1 | 2 | 1 |
| | 0 | 3 | 4 | 0 |
| | 1 | 3 | 4 | 0 |
| | 1 | 2 | 4 | 0 |
| | 1 | 3 | 4 | 0 |
| All 4 genes present | 0 | 2 | 4 | 0 |
Antimicrobial resistance profiles of 42 clinical V. parahaemolyticus isolates.
| Classify | Antimicrobial agent | |||
|---|---|---|---|---|
| No. (%)of R | No. (%)of I | No. (%)of S | ||
| β- lactam | Ampicillin | 42 (100.0) | 0 (0.0) | 0 (0.0) |
| Amoxicillin-Clavulanic | 0 (0.0) | 8 (19.0) | 34 (81.0) | |
| Piperacillin | 7 (16.7) | 16 (38.1) | 19 (45.2) | |
| Cefotaxime | 0 (0.0) | 0 (0.0) | 42 (100.0) | |
| Ceftazidime | 0 (0.0) | 0 (0.0) | 42 (100.0) | |
| Cefoxitin | 0 (0.0) | 21 (50.0) | 21 (50.0) | |
| Cephazolin | 16 (38.1) | 23 (54.8) | 3 (7.1) | |
| Imipenem | 0 (0.0) | 0 (0.0) | 42 (100.0) | |
| Meropenem | 0 (0.0) | 0 (0.0) | 42 (100.0) | |
| Tetracyclines | Tetracycline | 0 (0.0) | 2 (4.8) | 40 (95.2) |
| Aminoglycosides | Amikacin | 2 (4.8) | 36 (85.7) | 4 (9.5) |
| Gentamicin | 3 (7.1) | 27 (64.3) | 12 (28.6) | |
| Kanamycin | 3 (7.1) | 36 (85.7) | 3 (7.1) | |
| Streptomyein | 30 (71.4) | 12 (28.6) | 0 (0.0) | |
| Quinolones | Ciprofloxacin | 0 (0.0) | 11 (26.2) | 31 (73.8) |
| Levofloxacin | 0 (0.0) | 2 (4.8) | 40 (95.2) | |
| Chloramphenicol | Chloramphenicol | 0 (0.0) | 0 (0.0) | 42 (100.0) |
| Sulfonamides | Trimethoprim -sulfamethoxazole | 0 (0.0) | 0 (0.0) | 42 (100.0) |